Vaxcyte (PCVX) Just Gave Investors Something To Think About

Vaxcyte (PCVX) has moved back into focus after releasing positive topline OPUS-1 Phase 3 data for its VAX-31 pneumococcal vaccine, followed almost immediately by a combined US$1b equity and convertible debt raise.

Vaxcyte’s recent 17.68% 7 day share price return, on top of a 44.12% year to date share price gain and a 64.36% 1 year total shareholder return, points to building momentum as investors weigh the OPUS 1 data against dilution from the US$1b financing.

Scan how other vaccine and biotech players with recent data or funding catalysts are trading by reviewing the hand picked 35 healthcare AI stocks alongside Vaxcyte’s latest move.

Vaxcyte now trades at US$66.96 while published analyst targets cluster around US$114.78 and the modelled intrinsic value implies an even larger gap. How much of that spread still reflects mispricing after OPUS 1 and the US$1b raise?

Most Popular Narrative: 10.7% Undervalued

Vaxcyte’s most followed valuation storyline pegs fair value at $75, a touch above the last close at $66.96, and focuses on outcomes for late stage pneumococcal programs and manufacturing build out.

Multiple late stage PCV trials in adults and infants are scheduled to deliver top line immunogenicity and safety data over the next two years. These results could clarify the revenue path but also introduce binary clinical and regulatory risk that may limit visibility on future earnings.

See why 0 investors see Vaxcyte as 11% undervalued.

Result: Fair Value of $75 (UNDERVALUED)

Still, breakthroughs in the remaining OPUS trials or stronger than expected uptake assumptions for VAX-31 could quickly challenge the idea that Vaxcyte is only modestly undervalued.

Find out about the key risks to this Vaxcyte narrative.

Next Steps

Mixed signals on Vaxcyte so far, with meaningful upside arguments sitting alongside real downside questions. Move quickly, review the data in full, and weigh the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Vaxcyte?

If Vaxcyte has your attention, do not stop here. Broaden your watchlist with fresh ideas that match different risk levels, income goals, and balance sheet strength.

• Target potential mispricings by scanning companies that combine quality fundamentals with attractive entry points using the 29 high quality undervalued stocks.
• Build income potential into your portfolio by reviewing a curated set of higher yielding opportunities screened as 8 dividend fortresses.
• Prioritise resilience by focusing on financially robust businesses surfaced in the list of solid balance sheet and fundamentals (25 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com